Latest Quarter
2026-03-31
Serina Therapeutics Inc (SER)
Revenue
$0.0
Net Income
-$6.9M
Operating Margin
N/A
Free Cash Flow
-$17.2M
Debt / Assets
92.4%
Values are in USD and rounded to the nearest whole number unless noted.
Swipe horizontally to view all columns.
| Income Statement (Quarterly) | 2026-03-31 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 14,000 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | -42,000 |
| Operating Expenses | ||||
| R&D Expenses | 0 | 0 | 0 | 0 |
| SG&A Expenses | 3,081,000 | 2,907,000 | 3,170,000 | 2,911,000 |
| Operating Expenses | 6,280,000 | 5,858,000 | 5,549,000 | 5,312,000 |
| Operating Income | 0 | -5,858,000 | -5,549,000 | -5,312,000 |
| Interest Expense | -189,000 | 0 | 17,000 | 16,000 |
| Income Before Tax | -6,891,000 | -4,822,000 | -2,752,000 | 1,383,000 |
| Income Tax Expense | -7,000 | 0 | 0 | 0 |
| Net Income | -6,935,000 | -4,813,000 | -2,740,000 | 1,410,000 |
| Per Share | ||||
| EPS | -0.58 | -0.49 | -0.31 | 0.16 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Statement (Annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | 130,000 | 56,000 | 3,153,000 |
| Cost of Revenue | 85,000 | 194,000 | 90,000 |
| Gross Profit | 45,000 | -138,000 | -29,000 |
| Operating Expenses | |||
| R&D Expenses | 0 | 0 | 0 |
| SG&A Expenses | 10,997,000 | 9,430,000 | 3,894,000 |
| Operating Expenses | 24,022,000 | 16,910,000 | 6,129,000 |
| Operating Income | -24,022,000 | -17,048,000 | -3,129,000 |
| Interest Expense | 213,000 | 526,000 | 558,000 |
| Income Before Tax | -19,197,000 | -11,207,000 | 5,269,000 |
| Income Tax Expense | 18,000 | 0 | -8,000 |
| Net Income | -19,182,000 | -11,141,000 | 5,269,000 |
| Per Share | |||
| EPS | -1.91 | -1.51 | 0.63 |
| EPS Diluted | 0.00 | 0.00 | 0.00 |
| Balance Sheet (Quarterly) | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Assets | ||
| Cash and Cash Equivalents | 3,672,000 | 345,000 |
| Short Term Investments | 0 | 0 |
| Net Receivables | 0 | 57,000 |
| Inventory | 0 | 0 |
| Total Current Assets | 5,676,000 | 754,000 |
| Property Plant Equipment | 1,048,000 | 0 |
| Goodwill and Intangibles | 0 | 607,000 |
| Total Assets | 6,724,000 | 11,965,000 |
| Liabilities | ||
| Account Payables | 744,000 | 1,413,000 |
| Short Term Debt | 0 | 3,672,000 |
| Total Current Liabilities | 2,366,000 | 5,914,000 |
| Long Term Debt | 268,000 | 693,000 |
| Total Liabilities | 6,216,000 | 6,607,000 |
| Shareholders Equity | ||
| Retained Earnings | -44,318,000 | -131,013,000 |
| Total Shareholders Equity | 641,000 | 5,469,000 |
| Balance Sheet (Annual) | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Assets | ||
| Cash and Cash Equivalents | 3,672,000 | 345,000 |
| Short Term Investments | 0 | 0 |
| Net Receivables | 0 | 57,000 |
| Inventory | 0 | 0 |
| Total Current Assets | 5,676,000 | 754,000 |
| Property Plant Equipment | 1,048,000 | 0 |
| Goodwill and Intangibles | 0 | 607,000 |
| Total Assets | 6,724,000 | 11,965,000 |
| Liabilities | ||
| Account Payables | 744,000 | 1,413,000 |
| Short Term Debt | 0 | 3,672,000 |
| Total Current Liabilities | 2,366,000 | 5,914,000 |
| Long Term Debt | 268,000 | 693,000 |
| Total Liabilities | 6,216,000 | 6,607,000 |
| Shareholders Equity | ||
| Retained Earnings | -44,318,000 | -131,013,000 |
| Total Shareholders Equity | 641,000 | 5,469,000 |
| Cash Flow Statement (Quarterly) | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Operating Activities | ||
| Net Income | -11,207,000 | -14,803,000 |
| Depreciation & Amortization | 194,000 | 131,000 |
| Stock Based Compensation | 2,595,000 | 0 |
| Change in Working Capital | -3,316,000 | 625,000 |
| Operating Cash Flow | -17,137,000 | -7,800,000 |
| Investing Activities | ||
| Capital Expenditure | -22,000 | 0 |
| Investments | -22,000 | 0 |
| Investing Cash Flow | -22,000 | -10,000,000 |
| Financing Activities | ||
| Debt Repayment | 2,875,000 | -17,500,000 |
| Common Stock Issued/Repurchased | 5,000,000 | 0 |
| Dividends Paid | 0 | 0 |
| Financing Cash Flow | 13,212,000 | 17,500,000 |
| Summary | ||
| Free Cash Flow | -17,159,000 | -7,800,000 |
| Net Change in Cash | -3,947,000 | -300,000 |
| Cash Flow Statement (Annual) | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Operating Activities | ||
| Net Income | -11,207,000 | -14,803,000 |
| Depreciation & Amortization | 194,000 | 131,000 |
| Stock Based Compensation | 2,595,000 | 0 |
| Change in Working Capital | -3,316,000 | 625,000 |
| Operating Cash Flow | -17,137,000 | -7,800,000 |
| Investing Activities | ||
| Capital Expenditure | -22,000 | 0 |
| Investments | -22,000 | 0 |
| Investing Cash Flow | -22,000 | -10,000,000 |
| Financing Activities | ||
| Debt Repayment | 2,875,000 | -17,500,000 |
| Common Stock Issued/Repurchased | 5,000,000 | 0 |
| Dividends Paid | 0 | 0 |
| Financing Cash Flow | 13,212,000 | 17,500,000 |
| Summary | ||
| Free Cash Flow | -17,159,000 | -7,800,000 |
| Net Change in Cash | -3,947,000 | -300,000 |